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In this paper, the problem of predicting blood glucose concentrations (BG) for the treatment
of  patients with type 1 diabetes, is addressed. Predicting BG is of very high importance as
most  treatments, which consist in exogenous insulin injections, rely on the availability of BG
predictions. Many models that can be used for predicting BG are available in the literature.
However, it is widely admitted that it is almost impossible to perfectly model blood glucose
dynamics while still being able to identify model parameters using only blood glucose mea-
surements. The main contribution of this work is to propose a simple and identiﬁable linear
dynamical model, which is based on the static prediction model of standard therapy. It is
shown that the model parameters are intrinsically correlated with physician-set therapy
parameters and that the reduction of the number of model parameters to identify leads to
inferior data ﬁts but to equivalent or slightly improved prediction capabilities compared to
state-of-the-art models: a sign of an appropriate model structure and superior reliability.The validation of the proposed dynamic model is performed using data from the UVa sim-
ulator and real clinical data, and potential uses of the proposed model for state estimation
and  BG control are discussed.
© 2014 Elsevier Ireland Ltd. All rights reserved..  Introduction
ype 1 diabetes mellitus is an autoimmune disease that
estroys insulin producing beta cells. Since insulin stimulates
he uptake of glucose by cells, the lack of insulin leads to high
evels of BG. This condition, referred to as hyperglycemia,
s at the origin of numerous other medical conditions such
s blindness, nerve damage, vascular diseases, and so forth
∗ Corresponding author. Tel.: +41 216935168.
E-mail addresses: alain.bock@alumni.epﬂ.ch (A. Bock),
regory.francois@epﬂ.ch (G. Franc¸ois), denis.gillet@epﬂ.ch
D. Gillet).
ttp://dx.doi.org/10.1016/j.cmpb.2014.12.002
169-2607/© 2014 Elsevier Ireland Ltd. All rights reserved.[1]. Patients with Type 1 diabetes are typically treated by
exogenous insulin injections that replace endogenous pro-
duction. The amount of insulin, which can be administered
by means of an insulin pen or pump, needs to be carefully
computed, as an insulin overdose leads to low BG, i.e. to
hypoglycemia. Fainting, coma or even death may result from
hypoglycemia, which, thus, has to be avoided. Preventing
hyper- and hypoglycemia is complicated by the huge variabil-
ity of insulin absorption and action between patients, but also
within one patient [2]. Thus, predicting BG is a challenging
but crucial task, as most therapies rely, to some extent, on BG
predictions.
The development of reliable BG prediction models, that can
be used e.g. in bolus calculators, educational tools, insulin
 s i n108  c o m p u t e r m e t h o d s a n d p r o g r a m
pump suspension algorithms and closed-loop BG controllers,
is a very active research ﬁeld and many  prediction models are
now available in the literature. Some of these models, which
can be of very different nature, have been recently reviewed
and discussed by Steil et al. and Boutayeb et al. [3,4]. But
among all the available models, the most commonly used are
undoubtedly compartmental models. These models, whose
complexities rise from the simplicity of the minimal model
of Bergman [5] to the complexity of the models of Hovorka
et al. [6] or Dalla Man  et al. [7], e.g., show potentially good
prediction capabilities as long as they can be personalized
[8]. The personalization of the corresponding model parame-
ters is only possible if, together with BG, additional measured
quantities, such as insulin concentrations and tracer mea-
surements, are available. Unfortunately this is rarely the case
and prediction models that are identiﬁable with only BG mea-
surements should be preferred. This justiﬁes the widespread
use of black-box models, such as auto-regressive models [9],
or neural networks [10–12]. These models, however, have the
disadvantage that their parameters cannot be linked to phys-
ically observable quantities. As a result, identiﬁcation errors
which result in unlikely parameters cannot be easily detected
and predictions may become dangerously corrupted. Yates
and Watson therefore proposed recently to use a Maximum
A Posteriori method in combination with the minimal model
in order to do BG predictions [13]. However, this has the dis-
advantage of heavily relying on prior knowledge.
In this context, the contribution of this paper is to pro-
pose a new compartmental model that can be identiﬁed using
only BG measurements. Its simple linear structure, together
with its low number of model parameters and states, facili-
tates the identiﬁcation step and prevents ﬁtting measurement
noise. Additionally, it is proven that the corresponding models
parameters are related to the standard therapy parameters,
which have a physiological meaning. These are very valu-
able model properties for applications like continuous glucose
measurement signal ﬁltering, BG control (automated pancreas
or open loop control), state estimation, bolus calculators, or
pump suspension algorithms.
The paper is organized as follows: in Section 2, the new
Therapy Parameter-based Model (TPM) is presented and the
link between its parameters and standard therapy parameters
is discussed. In Section 3, the UVa simulator and clinical data
used to validate the model, the identiﬁcation method, and the
evaluation metrics are described. The validation method of the
TPM is presented in Section 4. This validation is performed in
3 successive steps: (i) the model is ﬁtted to the UVa simulator
and study data, (ii) the correlation between model and therapy
parameters is veriﬁed, and (iii) model predictions are analyzed
and compared. We conclude the paper in Section 5 and give an
outlook on future work.
2.  Therapy  parameter-based  modelIn this section, the model equations of the TPM are derived
from the Bergman Minimal Model and the relation between
TPM parameters and physician-set therapy parameters is
shown. b i o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123
2.1.  Model  derivation
2.1.1.  Bergman  minimal  model  (BMM)
Though originally designed to provide estimations of insulin
sensitivities based on intravenous glucose tolerance tests in
dogs and subsequently in humans [14], the BMM [5] has
recently been used for BG prediction and control [15–18] and
is found in modiﬁed versions, too [19]. One variation of the
Bergman minimal model equations is as follows:
dG(t)
dt
= −X(t)G(t) − SGG(t) + Uendo (1)
dX(t)
dt
= −p2(X(t) − SII(t)) (2)
where G is the BG concentration in mg dl−1, X is the insulin
action in
−1
min, SG is the glucose effectiveness at zero insulin
in
−1
min, SI is the insulin sensitivity in U−1 ·
−1
min · l, Uendo is the
endogenous glucose production in mg dl−1
−1
min, and p2 is the
inverse of time constant of the insulin action in
−1
min. I is the
plasma insulin concentration in U/l.
What makes the BMM appealing for prediction and control
is mainly its simple structure and its widespread acceptance,
although, to be used as a prediction model, it requires addi-
tional sub-models for meal contributions, insulin dynamics
and, optionally, physical activity [20]. However, the identi-
ﬁcation of BMM  parameters is only possible with a priori
knowledge [21] or using insulin concentration measurements
[22]. Identiﬁability can be improved by using sub-models such
as proposed by Kanderian et al. [23], provided the insulin con-
centration proﬁle I(t) is available. This is unfortunately not the
case in practice, as I(t) is not measured, and the identiﬁability
of the BMM is still an issue.
2.1.2.  Minimal  model  (MM)
Prud’homme et al. [24] recently extended the BMM  by substi-
tuting the insulin action and insulin absorption models [25] by
a 2nd-order insulin action model and by adding the 2nd-order
linear carbohydrates (CHO) sub-model by Hovorka et al. [26],
resulting in the following set of ODEs:
dG(t)
dt
= −X(t)G(t) − SGG(t) + Uendo + UG(t) (3)
dUG(t)
dt
= U˙G(t) (4)
dU˙G(t)
dt
= −2agU˙G(t) − a2gUG(t) + Kga2gUCHO(t) (5)
dX(t)
dt
= −axX(t) + axX1(t) (6)
dX1(t)
dt
= −axX1(t) + KxaxUI(t) (7)where the new states are the gut glucose absorption UG
in g
−1
min, its time derivative U˙G in g
−2
min, and the intermedi-
ate insulin action X1 in
−1
min. Additional model parameters are
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Fig. 1 – BG predictions using the LMM  with the same
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which furthermore increases correlation with therapy param-onstants 1/ax.
ntroduced: the meal sensitivity Kg in mg dl−1 g−1, the inverse
f the meal time constant ag in
−1
min, the insulin sensitivity Kx
n U−1 (different from SI), and the inverse of the insulin absorp-
ion/action time constant ax in
−1
min. The manipulated inputs
re the subcutaneous insulin infusion, UI in U ·
−1
min  and the
arbohydrate intake rate UCHO in g
−1
min. This model is referred
o as the Minimal model (MM)  in what follows.
The fact that the insulin concentration – which is neither
easured nor used – is not explicitly modeled improves the
dentiﬁability of this model compared to models using the
riginal Bergman minimal model insulin action of Eq. (2).
However, the results presented by Prud’homme et al. show
hat, despite improved identiﬁability and the use of prior
nowledge, the resulting predictions are still unsatisfactory
nd lead to sub-optimal insulin infusions. Another drawback
f the MM lies in the behavior induced by the bilinear term of
q. 3 (Eq. 1 for the BMM).  As such, Eq. 1 predicts that, for any
iven value X of the insulin action X(t), the reduction of the
lood glucose concentration is an increasing function of BG.
n other words, according to the term −X(t)G(t), high BG values
hould always lead to a large effect of a given insulin action
(t) on BG concentration (and vice-versa). This is however not
lways true, since the opposite effect has been observed in
ractice [27]. Especially prolonged hyperglycemia blunts the
ffect of insulin.
.1.3.  Linear  minimal  model  (LMM)
 simple yet effective approach to circumvent the limitations
f both the BMM  and MM is to linearize the BG equation.
s linearity is also advantageous for identiﬁcation and con-
rol purposes [28], several linearized versions of the minimal
odel are available in the literature. Linearizing the MM will
ead to the removal of the effect of glucose concentration on
he insulin efﬁciency. As said before, although many  mod-
ls (like the MM)  incorporate the bilinear term X(t)G(t), this
emoval can be physiologically justiﬁed since the increased
ffect of X on the variation of G at high BG concentrations can-
ot be observed in real patients [27]. It has been shown that o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123 109
the performances of both the minimal model and the LMM
are comparable, though none ﬁts all the available data [29].
Linearized minimal models were also used for predicting BG,
with limited success [16]. The LMM presented here and used
thereafter is a linear version of the MM that reads:
dG(t)
dt
= −X(t) − SGG(t) + Uendo + UG(t) (8)
dUG(t)
dt
= U˙G(t) (9)
dU˙G(t)
dt
= −2agU˙G(t) − a2gUG(t) + Kga2gUCHO(t) (10)
dX(t)
dt
= −axX(t) + axX1(t) (11)
dX1(t)
dt
= −axX1(t) + KxaxUI(t) (12)
with the insulin sensitivity Kx being now in mg  dl−1 · U−1.
Despite the removal of the bilinear term, the LMM is still
not very efﬁcient in terms of steady-state predictions. In fact,
if no insulin bolus is infused and no meal is ingested, steady-
state BG concentration is obtained by setting all inputs and
time derivatives to 0 in Eqs. (8)–(12) and reads:
Gss =
Uendo − KxUI,b
SG
(13)
where UI,b is the corresponding basal insulin infusion. Typi-
cal values of Gss are around 100 mg dl−1, when adequate UI,b
are infused. However this is rarely the case as shown in Sec-
tion 4.1.1.
As such, the steady-state BG concentration predicted by
the LMM does not depend on a patient’s initial BG. For exam-
ple all the aforementioned models predict recovery even
when a patient in hyperglycemic condition does not take
counteractive actions. This is in contradiction with practi-
cal observations that showed that in such a case, the patient
will typically remain in hyperglycemic condition. Also, the
parameters Uendo and SG directly inﬂuence the identiﬁcation
of insulin and meal parameters, which makes identiﬁcation
particularly prone to model mismatch – which is inevitable in
such a high noise and perturbation-rich environment. Indeed,
the couples of insulin and meal time constants and sensi-
tivities, i.e. (ax,Kx) and (ag,Kg), respectively, are dependent.
This latter issue is illustrated by Fig. 1, where it is shown
that the time constant 1/ax inﬂuences the amplitude of an
insulin injection-related drop in BG. To obtain meaningful
model parameters the amplitude and the rate of the effect of
meal and/or insulin on BG concentration have to be decoupled,eters (cf. Sections 4.1.1 and 4.2.2). Therefore this inﬂuence
should be eliminated, making ax and ag independent of the
respective response amplitudes.
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Fig. 2 – BG predictions using the TPM with the same insulin
sensitivity Kx and inputs, but two different time constants
1/ax.
2.1.4.  Therapy  parameter-based  model  (TPM)
To improve the LMM, it is proposed to remove Uendo and SG,
leading to the following set of ODEs:
dG(t)
dt
= −X(t) + UG(t) (14)
dUG(t)
dt
= U˙G(t) (15)
dU˙G(t)
dt
= −2agU˙G(t) − a2gUG(t) + Kga2gUCHO(t) (16)
dX(t)
dt
= −axX(t) + axX1(t) (17)
dX1(t)
dt
= −axX1(t) + KxaxUI(t) (18)
The removal of Uendo and SG leads to the following changes
in the properties of the resulting dynamical model properties:
• After an insulin bolus or a meal, BG drops or rises, respec-
tively, as a second-order dynamical system.
• Gss only varies with Kx, Kg, and the initial BG concentration:
Gss = G(0) − KxUI,tot + KgUCHO,tot (19)
where G(0) is the initial BG, UI,tot =
∫ tf
0
UI(t)dt is the total
amount of infused insulin between the initial time and the
ﬁnal time tf, and UCHO,tot =
∫ tf
0
UCHO(t)dt is the total amount
of ingested CHO between the initial time and the ﬁnal time
tf.
• As depicted in Fig. 2, the sensitivities are now decoupled
from their respective time constants.
• The number of parameters to identify has been reduced
from 6 to 4.By coincidence, Kirchsteiger et al. used the same model
as the TPM to predict BG concentrations on real patient data
[30]. However, neither a comparison to other models was per-
formed, nor a link to therapy parameters was established. b i o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123
Percival et al. developed a similar model with ﬁrst-order
dynamics and a pure time delay [31]. However, the correspond-
ing simulated BG proﬁles are not smooth and the time delay
is difﬁcult to identify. Also, their correlation analysis showed
that the identiﬁed parameters were not signiﬁcantly corre-
lated to therapy parameters.
2.2.  Standard  therapy
In this subsection, the principles of the standard bolus and
insulin pump therapy are described and it is shown how ther-
apy parameters are related to the parameters of the TPM.
2.2.1.  Standard  therapy  deﬁnition
Patients with type 1 diabetes typically:
• Take a ﬁngerstick BG measurement (Gm) before a meal, or
whenever they suspect their BG to be high,
• Compare Gm to the target BG (Gt), and compute the differ-
ence: G = Gm − Gt.
• Compute the correction bolus as Icorr = G/CF, with CF being
the correction factor in mg dl−1 · U−1. Icorr may be negative if
the patient plans to ingest a meal.
• Compute the meal bolus as Imeal = I2C · CHO, with I2C being
the insulin-to-carbohydrates ratio in U · g−1, and CHO being
the corresponding weight of carbohydrates in g.
• Inject the bolus I = Icorr + Imeal using their insulin pump or
pen.
Indeed, CF and I2C correspond to the therapy parame-
ters and are set by a physician. CF quantiﬁes the drop in BG
resulting from a 1U insulin injection at steady-state, while I2C
indicates how much insulin should be injected per gram of
ingested carbohydrates. MS  = I2C · CF can thus be deﬁned as
the meal sensitivity, which indicates the increase in BG per
gram of ingested carbohydrates.
From the viewpoint of systems theory, a way to interpret
the standard therapy parameters MS and CF is by assimilat-
ing them to the parameters of a static model, identiﬁed by
physicians, that maps the amount of insulin to the future
steady-state BG.
2.2.2.  Basal  insulin
With an insulin pump, insulin may be infused almost con-
tinuously. This basal rate is useful in that it counteracts
circadian variations in insulin sensitivity, such as the dawn
effect. It is generally tuned by a physician in such a way that,
in the absence of disturbances (such as meals or physical
activity), BG stays approximately at the target value through-
out the day. Hereafter, we will always assume a properly
set basal rate. In this case, basal insulin is not considered
as an input, i.e. inputs correspond exclusively to insulin
boluses.
2.2.3.  Relation  between  therapy  parameters  and  the  TPMProposition 2.1. The TPM parameter Kx is equal to the therapy
parameter CF.
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Fig. 3 – TPM simulations after an insulin bolus (left-handc o m p u t e r m e t h o d s a n d p r o g r a m s 
roof 2.2. If a 1U insulin bolus is infused at t = 0, UI(s) = 1 and, in
he absence of previous insulin boluses and meals, CF,  accord-
ng to the deﬁnition given in Section 2.2, is given as:
F = −(G(∞) − G(0)) (20)
here G(∞) is the BG at steady-state and G(0) the initial BG.
(s) = − Kx
s
(
1 + 1ax s
)2 UI(s) + 1s G(0) (21)
pplying the ﬁnal value theorem leads to:
G(∞) = lim
s→0
sG(s)
= −lim
s→0
Kx(
1 + 1
ax
s
)2 − G(0)
= −Kx − G(0)
hus,
x = −(G(∞) − G(0)) = CF (22)
hich concludes the proof.
roposition 2.3. The TPM parameter Kg is equal to the therapy
arameter MS.
roof 2.4. If 1 g of CHO is ingested at t = 0, and in the absence
f previous insulin boluses and meals, MS,  according to its
eﬁnition (see Section 2.2), reads:
S  = G(∞) − G(0) (23)
he rest of the proof is straightforward and is similar to that
f Proposition 1. 
As shown, the therapy parameters CF and MS correspond
y construction to the model parameters Kx and Kg of the TPM,
espectively. Both indicate how much BG will drop or rise,
espectively, in between consecutive steady states. In other
ords, the TPM may be considered as a dynamical extension
f the standard, static, therapy model. This property is illus-
rated in Fig. 3, while experimental veriﬁcation of this link is
resented in Section 4.2.2.
The main advantage of TPM compared to the standard ther-
py model lies in its ability to predict BG evolution over time.
hus, TPM may be used for predictions, control, and other
pplications requesting time-varying BG concentrations. The
ink between therapy and model parameters is very valuable,
ecause TPM parameters have a physical meaning that is rec-
gnized by physicians and may therefore be accepted more
asily. On the other hand, a priori knowledge of the physician-
et therapy parameters can be used, if available, to improve the
eliability of the TPM parameters.On the other hand, no explicit link between therapy
arameters and parameters of the LMM  and the MM can be
stablished, because these models have a stead-state behav-
or that is not compatible with the deﬁnition of CF and MS.side) and a meal (right-hand side).
In fact, with these models, if time goes to inﬁnity, simulated
BG concentration will tend to the value deﬁned in Eq. (13),
irrespective of the initial BG concentration. However, it does
make sense to compare the values of Kg and Kx to MS and CF,
respectively, because these parameters deﬁne the amplitude
of the rise or drop in BG concentration. As will be seen in Sec-
tion 4, these values are correlated. Hence, such a comparison
will be performed in the next sections, but it has to be clear
that this comparison is not performed to quantify the correla-
tion between the parameters of the MM or of the LMM  to the
therapy parameters as such, but rather to highlight the intrin-
sic higher correlation degrees between the parameters of the
TPM and the therapy parameters, which is one of the main
added-values of the TPM.
3.  Validation  tools  and  methods
This section describes the data used for the validation of the
TPM as well as the practical methods and tools.
3.1.  UVa  simulator
For model validation, a ﬁrst step is to test the models on virtual
patients. For this reason the UVa-Padova simulator, based on
the model by Dalla Man et al. [7,32] and approved by the FDA
to replace animal testing in the context of closed-loop control,
has been used to generate data sets.
 s i n112  c o m p u t e r m e t h o d s a n d p r o g r a m
We  evaluate the models on 4 days that have been chosen
in the following way:
• The ﬁrst three days are similar. An insulin bolus and a meal
are taken simultaneously at 8 AM,  but are varied from day to
day to span the whole BG range. This way the nonlinearities
of the UVa model are taken into account. The insulin bolus
is chosen such that it decreases BG concentrations by 10, 70
and 120 mg/dl, respectively. The exact amount is calculated
using the CF that is given in the simulator. The meals are
then given such that they counteract these boluses based
on the I2C provided in the simulator. Meal durations where
chosen to be 10, 20, and 10 min, respectively.
• The fourth day spans the whole palette of BG concentra-
tions and incorporates different amounts of carbohydrate
ingestion and insulin injections. Boli reducing BG by approx-
imately 100, 5, 10, and 15 mg/dl are given respectively at 10
AM,  2 PM,  3 PM and 4 PM.  Meals, rising BG by approximately
80, 20, and 10 mg/dl are taken respectively at 8 AM, 2 PM,
and 6 PM.  Meal durations are 10, 15, and 20 min.
The noiseless measurements of the 10 adults are used and
are sampled with a period of 15 min. On days 1 to 3, data
between 8 AM and 4 PM are considered. On day 4, data between
8 AM and 11 PM are used. All patients have their standard basal
insulin administered during this time.
3.2.  Clinical  study
Data used for model validation are extracted from a
mono-center and open-label study, designed to evaluate an
investigational meal bolus advice method, similar to that of
Prud’homme et al. [24]. 12 subjects with type 1 diabetes mel-
litus followed the same 10-day procedure:
• Clinical habituation phase: The objective of the 3 ﬁrst days
was to get the subjects used to the clinical environment
and changes in their daily routine. Meanwhile, physicians
adjusted the therapy parameters. On day 3, an additional
basal rate test was performed to verify and adapt the basal
rate.
• Sensitivity tests: On days 4 and 5, insulin sensitivity tests
were performed, i.e. patients received an isolated insulin
shot, followed by BG monitoring. The goal was to observe
the effect of insulin without the inﬂuence of any meal
perturbation, which is key for obtaining reliable insulin
action parameters (Section 3.4). Whenever necessary, the
basal rate was slightly reduced a few hours before the test,
so that at 8:30 AM a corrective bolus could be infused. Until
11:30 AM,  the sampling period for SMBG measurements was
set equal to 15 min.
• Standard therapy days: On days 6 and 7, standard therapy was
applied (Section 2.2). At 9:00 AM,  the subjects received the
test meal and infused their standard insulin bolus. BG was
measured every 30 min  until 4:00 PM.
• Optimized insulin infusion days: On days 8 to 10, optimized
insulin patterns were infused under the same meal and
BG measurements conditions than before. The therapy b i o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123
consisted of small insulin boluses, potentially administered
every 30 min  until 2:00 PM.
SMBG measurements were performed with Accu-Chek®
Combo meters, while test meals were always the same fatty,
heavy and long-lasting meals (750 kcal with 25–30% carbohy-
drates, 15–20% protein, and 55–60% fat). The following data
were not considered for model validation:
• Data collected after a hypoglycemic intervention.
• Data collected after the intake of medication.
• Data with very high variability and unexplained BG excur-
sions.
Of note is that this corresponds to the exclusion of 2
subjects. Overall, the standard therapy I2C was often underes-
timated leading to high BG concentrations, most likely due to
the slow nature of the selected meal. Therapy parameter val-
ues were updated on a day-to-day basis. For the validation of
the TPM, we  only consider one single therapy parameter value
per patient.
The data from this study are very well suited to analyze
parameter correlations and compare model predictions since:
• insulin sensitivity tests were performed (cf. Section 3.4).
• the patients had the same meal several times on con-
secutive days, which prevents that parameters change
signiﬁcantly over the course of the study.
• the basal rates and therapy parameters were very well
adjusted by physicians.
• two different insulin infusion strategies were used.
The latter is interesting in that, generally speaking, if all study
days are similar, models that have good data ﬁts generate good
predictions even if they have inappropriate dynamics. On the
other hand, an even more  diversiﬁed study design with, e.g.,
modiﬁed meal sizes, more  patients and more  insulin sensitiv-
ity test days, would improve the quality of the data further.
3.3.  Identiﬁcation  method
Model parameters identiﬁcation is performed by minimizing
the following weighted least squares objective function J:
J() =
D∑
d=1
˛dJd() (24)
where  is the vector of model parameters to estimate
( = [ax ag Kx Kg]T for the TPM, e.g.), D is the number of days,
˛d is the weight associated to day d, and Jd is deﬁned for each
day d:
Jd() =
Nd∑
i=1
(Gd,i − Gˆd,i())
2
(25)where Nd is the number of BG measurements for day d, Gd,i
and Gˆd,i are the measured and simulated BG concentrations
on day d, respectively.
i n b i o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123 113
c
m
s
a
s
t
3
P
a
i
c
t
c
N
i
a
t
t
t
l
w
t
t
h
s
I
t
i
i
3
A
f
t
p
t
d
3
T
d
M
w
06:00 09:00 12:00 15:00 18:00
50
60
70
80
90
Time of the day
BG
 c
on
ce
nt
ra
tio
n 
(m
g/d
l)
BG concentration with meal and bolus
K
x
 = 20
K
x
 = 10
06:00 09:00 12:00 15:00 18:00
50
60
70
80
90
Time of the day
BG
 c
on
ce
nt
ra
tio
n 
(m
g/d
l)
BG concentration with only insulin bolus
K
x
 = 20
K
x
 = 10
Fig. 4 – Simulations of the therapy parameter-based model
with simultaneous insulin bolus and meal (left) and only
an insulin bolus (right). The parameters are chosen as
follows: ax = 0.04, ag = 0.03,
Kg
Kx
(= I2C) = 0.1 and Kx is chosen
according to legend. The insulin bolus is 2U and the meal isc o m p u t e r m e t h o d s a n d p r o g r a m s 
The optimal values * are such that they minimize the
umulated (and weighted) prediction error:
in

J() =
D∑
d=1
(
˛d
(
Nd∑
i=1
(Gd,i − Gˆd,i())
2
))
(26)
.t.ModelEquations (27)
where the Model equations (Eqs. (14)–(18) for the TPM, e.g.)
re integrated to compute the predicted values Gˆd,i() at the
ampling instant i of day d under the same conditions than
he corresponding measured values Gd,i, for any choice of .
.4.  Reliable  insulin  action
articular attention has to be paid to the estimation of insulin
ction, as, for instance, underestimating the insulin effect
ncreases the risk of overdosing insulin. It is made more
omplicated when meals and insulin boluses are taken simul-
aneously, since the effects of carbohydrates and insulin
ancel each other out, especially if they act at similar speeds.
ote that this remark further justiﬁes the choice of slow meals
n the context of the clinical study associated with this paper,
s the meals taken by the subjects were mostly slower than
he insulin actions.
This difﬁculty to identify insulin parameters – worsened by
he high noise level – is depicted in Fig. 4. It shows that when
he meal and the bolus are taken simultaneously, the simu-
ated BG does not change signiﬁcantly when Kx is doubled,
hile the right-hand side plot shows the large sensitivity of
he simulated BG proﬁle to a change in Kx when the meal and
he bolus are taken separately. In other words, Fig. 4 illustrates
ow difﬁcult it is to reliably identify Kx on the basis of BG mea-
urements if the meal and the bolus are taken simultaneously.
ndeed, in such a case, it is possible to estimate the ratio KgKx
hat corresponds to I2C, but not Kx (corresponding to CF).
To eliminate this problem, the only solution is to perform
nsulin sensitivity tests, where a bolus without a correspond-
ng meal is infused.
.5.  Choice  of  metrics
 good overview of the different metrics used to compare dif-
erent BG proﬁles is given by Del Favero et al. [33]. Additionally,
he authors propose an extension of existing metrics to incor-
orate a glucose speciﬁc penalty.
In this paper, we propose to assess the quality of the LMM,
he MM and the TPM by three different indicators, which are
etailed below.
.5.1.  The  mean  absolute  difference  (MAD)
he MAD  is used to compare data ﬁts, as well as model pre-
ictions resulting from the different investigated models.
1
N∑AD  =
N
t=1
|G(t) − Gˆ(t)| (28)
here N denotes the number of samples.20g.
3.5.2.  The  coefﬁcient  of  determination
The coefﬁcient of determination R2 in % is deﬁned as:
R2 = 100
⎛
⎜⎜⎜⎜⎝1 −
1
N
N∑
t=1
(G(t) − Gˆ(t))2
1
N
N∑
t=1
(G(t) − G¯)2
⎞
⎟⎟⎟⎟⎠ (29)
where G¯ is the average BG: G¯ = 1N
∑N
t=1G(t). A value of 100% is
equivalent to a perfect ﬁt, while worse ﬁts may have negative
values. This method is more  sensitive to outliers because of
its quadratic term.
In this paper it is not necessary to use the glucose spe-
ciﬁc metrics since hypo- and hyperglycemia conditions rarely
occurred during the clinical study.
3.5.3.  The  error  grid  analysis  (EGA)
As BG predictions are thought to be, in the ideal case, used
in the same way as BG measurements, they should also be
evaluated using the EGA [34], which is used to assess the per-
formances of BG meters. BG measurements are compared to
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Fig. 6 – Boxplot of the MAD  and R2 of the data ﬁt of every
patient (n = 10). Comparison between different prediction
production and glucose effectiveness at zero insulin, result-
ing in different behavior at steady-state. The UVa model,on UVa data.
reference BG measurements and are classiﬁed via a grid that
rates resulting treatment decisions.
• If the measurement is “clinically accurate”, i.e. if it deviates
by no more  than 20%, it is classiﬁed in zone A. If 95% of the
measurements are in zone A, the BG meter is approximately
achieving the standards of the ISO 15197 norm. However, as
shown by Freckmann et al. [35], many  current BG meters do
not fulﬁll this norm.
• If a measurement is “clinically appropriate”, i.e. if it would
lead to benign or no treatment, it is classiﬁed in zone A and
B.
• All other zones are considered potentially dangerous and
should therefore be avoided.Clearly, it is highly desired to obtain as many  predictions
in zone A as possible, and to avoid zones other than A or B.
Table 1 – MAD  and R2 indicators (averaged over all
patients) for the three investigated models on UVa
simulator data.
TPM LMM MM
MAD in mg/dl 6.91 4.94 5.26
R2 in % 89.6 94.8 94.0models on UVa simulator data.
4.  Validation
The validation of TPM is performed with the UVa simulator
data of Section 3.1 and the clinical study data of Section 3.2
and follows 3 separate steps: (i) the data ﬁts are analyzed,
(ii) the correlation between therapy and model parameters is
checked, and (iii), model predictions are evaluated.
4.1.  UVa  simulations
4.1.1.  Data  ﬁt
The structure of the TPM mainly differs from that of the
other models because of the absence of endogenous glucosehowever, has similar steady-state behavior as the MM  and
Table 2 – Different correlation factors and their relative p
values (in brackets) between therapy parameters
provided in the UVa simulator and identiﬁed parameters
on UVa simulator data (n = 10).
Correction factor Ins-to-carb ratio Meal sensitivity
MM −0.20 (0.58) −0.02 (0.95)
LMM 0.14 (0.70) 0.98 (2.6·  10−7) 0.11 (0.77)
TPM 0.91 (0.0002) 0.99 (1.6·10−8) 0.71 (0.2)
c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123 115
0 1 2 3 4 5 6
0
10
20
30
40
50
MM: Correction factor (mg.dl−1.U−1) and K
x
 (1/U)
Kg (Identified)C
or
re
ct
io
n 
fa
ct
or
 (p
rov
ide
d i
n U
Va
 si
mu
lat
or)
0 20 40 60 80 100
0
1
2
3
4
MM: Meal sensitivity and Kg (mg.dl
−1
.g−1)
Kg (Identified)M
ea
l s
en
si
tiv
ity
 (p
rov
ide
d i
n U
Va
 si
mu
lat
or)
0 50 100 150
0
10
20
30
40
50
LMM: Correction factor and K
x
 (mg.dl−1.U−1 )
K
x
 (Identified)Co
rre
ct
io
n 
fa
ct
or
 (p
rov
ide
d i
n U
Va
 si
mu
lat
or)
0 5 10 15 20 25
0
5
10
15
20
25
LMM: Meal sensitivity and Kg (mg.dl
−1
.g−1)
Kg (Identified)M
ea
l s
en
si
tiv
ity
 (p
rov
ide
d i
n U
Va
 si
mu
lat
or)
0 10 20 30 40 50
0
10
20
30
40
50
TPM: Correction factor (mg.dl−1.U−1 )
Correction factor (Identified) = K
x
Co
rre
ct
io
n 
fa
ct
or
 (p
rov
ide
d i
n U
Va
 si
mu
lat
or)
0 0.05 0.1 0.15 0.2
0
0.05
0.1
0.15
0.2
TPM: Insulin−to−carbohydrates ratio (U/gCHO)
I2C (Identified) = Kg/K x
I2
C 
(P
rov
ide
d i
n U
Va
 si
mu
lat
or)
Fig. 7 – Comparison of physician-set therapy parameters and identiﬁed model parameters to illustrate correlation results on
UVa simulator data (n = 10).
L
s
s
a
m
S
mMM  that the TPM is not able to reproduce. For this rea-
on, no insulin sensitivity tests are done with the UVa
imulator – the TPM does not have the dynamics to be
ble to ﬁt such data. This situation is not optimal and
ay result in unreliable insulin action, as explained in
ection 3.4, but the challenge is the same for each tested
odel.For the identiﬁcation of UVa simulator data, the weight
between the different days is equal, i.e. ˛d = 1 for all days d.
All data are used for the evaluation of ﬁtting performance
(D = 4), leading to one parameter set for each patient. Initial BG
is computed via linear interpolation between the values just
before and right after the ﬁrst measurement used for identi-
ﬁcation. The initialization of the other states is performed by
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Table 3 – Different correlation factors and their relative
/itp values (in brackets) between therapy parameters
provided in the UVa simulator and identiﬁed parameters
on UVa simulator data without Adult 9.
Correction factor Ins-to-carb ratio Meal sensitivity
MM 0.77(0.014) 0.62 (0.075)
does not allow to identify this subject. In fact some boundsLMM 0.86 (0.0028) 0.99 (9.76·10−7) 0.69 (0.038)
TPM 0.90 (0.00078) 0.99 (1.01·10−7) 0.74 (0.023)
propagating past model inputs. Examples of such simulations
are given in Fig. 5.
Table 1 shows that LMM  and the MM have comparable
ﬁtting capabilities on UVa simulator data, while the TPM
is slightly lower. This fact was expected as the number of
model parameters of the TPM is lower. However, as it will be
seen in Sections 4.1.2 and 4.1.3, this small decrease in the ﬁt-
ting capability is largely compensated by the improvement in
parameter identiﬁability and prediction performance.
Indeed, good model ﬁts do not necessarily imply good
model predictions. With a high number of parameters, a
model is typically able to generate many  different BG pro-
ﬁles, leading to good data ﬁts even though the dynamics of
the model are not appropriate. However, in such a case, model
predictions will not be good when the data set used for vali-
dation differs from that used for identiﬁcation. Conversely, a
model with less parameters may have inferior ﬁtting capabili-
ties but better predictions capabilities if its dynamics are more
appropriate. This effect increases with the presence of mea-
surement noise (which is high in our case), because having
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more  parameters to identify increases the risk of ﬁtting the
noise. To summarize, a model with more  appropriate dynam-
ics, but less parameters will have potentially worse data ﬁts,
but better model predictions than a model with a high number
of parameters, but less appropriate dynamics. The variability
on parameter identiﬁcations is similar for all models as shown
in Fig. 6 and shows few signiﬁcant outliers.
4.1.2.  Correlation  analysis
In this subsection, we  experimentally verify the relation
between the therapy parameters provided in the UVa simula-
tor and those identiﬁed using the models by analyzing their
correlation. D = 4 and ˛d = 1 for all d as in Section 4.1.1. It is
not clear how the therapy parameters provided in the UVa
simulator were determined, but simulations show that they
are accurate.
To calculate the correlation factor, the correlation between
the therapy parameter values provided in the UVa simulator
and the identiﬁed parameter values are used. In other words,
we are comparing MS  to Kg and CF to Kx.
The results are summarized in Table 2 and illustrated in
Fig. 7. It can be observed that for the LMM  and the MM,  there
is one outlier patient that corresponds to Adult 9 of the UVa
standard database. This subject was previously identiﬁed as
an abnormal subject [36]. The structure of these two  modelsthat are set on the parameters in the identiﬁcation are attained
and show that the computed parameter values are unrealistic.
This outlier heavily inﬂuences the comparison of correlation
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Fig. 9 – Example of data ﬁts for different prediction models
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Fig. 10 – Boxplot of the MAD  and Ry2  of the data ﬁt of every
patient (n = 10). Comparison between different prediction
models on clinical data.
Given a prediction horizon of h minutes, model predictionsn clinical data.
actors given in Table 2. For this reason, the correlation anal-
sis without Adult 9 is shown in Table 3.
When not considering Adult 9, the identiﬁed parameters of
ll models (except Kg of the MM)  are correlated (p < 0.05) to their
espective values provided with the UVa simulator. However,
he correlation factors of the TPM are much higher than those
f the other two models, indicating that the TPM is capable of
eliably identifying therapy parameters. These are excellent
esults for the TPM, considering that no speciﬁc insulin sensi-
ivity tests could be included in the identiﬁcation. It should be
oted that TPM parameters for Adult 9 were correctly iden-
iﬁed. The correlation factors for the LMM are higher than
hose of the MM,  indicating that its structure is more  appro-
riate. Also, the insulin-to-carbohydrates ratio is accurately
dentiﬁed by the LMM,  which indicates that, as discussed in
ection 3.4, the LMM  is not capable to reliably identify Kg and
x in the absence of insulin sensitivity tests.
Table 4 – MAD  and R2 indicators (averaged over all
patients) for the three investigated models on clinical
data.
TPM LMM MM
MAD in mg/dl 12.89 10.56 12.09
R2 in % 72.42 81.16 76.15Removing Adult 9 from the data ﬁt analysis (Section (4.1.1)
does not signiﬁcantly change the results, since its data ﬁts
were a little below average for all models, but not outliers.
4.1.3.  BG  predictions
In this section, we compare prediction capabilities of the TPM
to those of the MM and the LMM.
To obtain reliable results, the data used for identiﬁcation
(training data) should not be used for validation (validation
data). In this study, we perform cross-validation: in the case of
UVa simulator data, model parameters are identiﬁed on 3 data
sets and validated on the 4th, for all possible permutations
of the data sets. Thus, we obtain 4 parameters sets with the
corresponding predictions for every subject, which total up to
40 different parameter sets.are done as follows:
Table 5 – Different correlation factors and their relative p
values (in brackets) between physician-set and
identiﬁed parameters on clinical data.
Correction factor Ins-to-carb ratio Meal sensitivity
MM 0.16 (0.67) 0.57 (0.09)
LMM 0.47 (0.17) 0.78 (0.0077) 0.52 (0.13)
TPM 0.89 (0.00055) 0.89 (0.00055) 0.85 (0.002)
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Fig. 11 – Comparison of physician-set therapy parameters and identiﬁed model parameters to illustrate correlation results
on clinical data.• A validation data set with corresponding model parameters
(identiﬁed on training data) for a given patient and day is
chosen.
• For every available BG measurement we  start to simulate
the model h minutes earlier. The initial BG values are set
to the measured value preceding the h-minute simulation
(this is different to the identiﬁcation because future values
are assumed unknown). All other states are initialized using
simulations with model inputs dating back several hours
before the beginning of the simulation.• The BG value after the h-minute simulation is the predicted
BG and coincides with an experimental measurement point.
• The evaluation metrics are evaluated on all prediction
points.
• Finally, the results are averaged over all parameters sets for
comparison purposes.For comparison, we also show the results of a Zero Order
Hold (ZOH) model, which is often used as a reference. It con-
sists in setting the predicted BG value to the initial BG value. In
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has a higher correlation factor, although the results fromodels on clinical data.
ther words, we  consider BG concentrations to stay constant
ver the prediction horizon.
We  do predictions with horizons reaching from h = 15 min-
tes to h = 165 min  with 15 min  increments. The prediction
esults of all models are compared in Fig. 8. We  compare (i)
he MAD,  which measures the prediction ﬁt quality, and (ii)
he percentage of predictions in Clarke EGA zone A, which
uantiﬁes patient safety. In these graphs, for each prediction
orizon, the averaged value over all possible combinations and
ll patients is given, as well as the corresponding standard
eviation.
For small prediction horizons up to 60 min, the TPM gives
etter MAD  values than all other models. For longer prediction
orizons, the MM  is the most effective, followed by the LMM
nd the TPM.
The percentage in zone A of the Clarke EGA shows similar
esults. This is caused by the steady-state behavior of the MM
hat is closer to that of the UVa simulator model (which always
onverges to a value independently of the inputs) than the
PM. All model predictions, except for the ZOH, are within
ones A and B of the EGA. Overall, the difference between the
ifferent models is small and not statistically signiﬁcant.
If Adult 9 is disregarded, only small changes are observed
n the results.
It can be concluded that for predicting BG on UVa simulator
ata, the TPM is an excellent choice because, despite having o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123 119
less parameters, worse data ﬁts, and a model structure that
is not fully compatible with the UVa simulator model, it is
superior or comparable to the other models in terms of predic-
tion performance, model identiﬁability and therapy parameter
correlation.
4.2.  Clinical  data
4.2.1.  Data  ﬁt
On the clinical study data the data ﬁts are computed in the
same way as described in Section 4.1.1, with a few exceptions:
(i) the model parameters are identiﬁed with D = 7 (i.e. the full
data set is used). (ii) As discussed in Section 3.4, to be able to
identify Kx, the sensitivity tests described in Section 3.2 were
performed. However, 2 sensitivity test days out of 7 were insuf-
ﬁcient. For this reason, the weight of the insulin sensitivity
test days was increased by 5 – the value that showed the best
results. Thus, the objective function deﬁned in Eq. (26) used
˛4 = ˛5 = 5 and ˛d = 1 otherwise. Ideally, more  sensitivity tests
should be performed, so that they outweigh the meal tests.
Examples of data ﬁts are given in Fig. 9, while Table 4 com-
pares the performances of the TPM, the LMM, and the MM in
terms of the MAD and R2 indicators.
The LMM shows the best ﬁtting capabilities. Hence, the
structure of the LMM is more  appropriate than the MM struc-
ture, as both have 6 parameters to identify. The performances
of the TPM and the MM are comparable, with a slight advan-
tage for the MM. Fig. 10 depicts the variability of data ﬁts,
that is the lowest for the LMM and increases for the MM and
the TPM. A higher variability is due to a higher number of
patients that were more  difﬁcult to ﬁt. However, it will be seen
in Sections 4.2.2 and 4.2.3 that this is not detrimental to nei-
ther parameter identiﬁcation nor model prediction, the reason
being that some patients have intrinsically higher variability
in their BG concentrations. The lower variability for the LMM
and MM can be attributed to model mismatch and noise ﬁtting,
rather than to model structures.
For 4 patients out of 10, the values of SG and Uendo collapsed
to 0, with the consequence that the LMM becomes identical to
the TPM and that the corresponding model ﬁts are very close.
4.2.2.  Correlation  analysis
The correlation analysis on clinical data is done in the same
way as for UVa simulator data in Section 4.1.2, with the excep-
tion that physician-set therapy parameter values are used
instead of those provided in the UVa simulator. Similarly to
Section 4.2.1, the identiﬁcation of the TPM parameters is per-
formed with the full set of data, i.e. D = 7, and the same ˛.
The results are summarized in Table 5 and illustrated
in Fig. 11. The parameters of the MM are not correlated
with the physician-set parameters and the correlation of
the correction factor is very low, indicating a dangerously
unreliable insulin action. Also, the identiﬁed values of Kx
have some outliers with very high values (compared to the
corresponding physician-set counterparts), which can be due
to high values of Uendo. The meal sensitivity on the other handFig. 11 show that the Kg parameter has low sensitivity. High
Kg values should lead to high Kx values (cf. Section 3.4), but
this is not the case, probably due to high values of SG. The
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Fig. 13 – MAD  (top) and % in EGA zone A (bottom) of the averaged model predictions (n = 58) for the different prediction
tandmodels on clinical data. Mean values are given on the left, s
overestimation of the meal effect is to be avoided as it could
lead to the computation of potentially massive insulin doses.
Similar results were found for the identiﬁcation of Kg with
the LMM.  Though the correlation of Kx and the correction fac-
tor are improved by the LMM  structure, this improvement is
not signiﬁcant.
On the other hand, with the TPM, all model parameters
are signiﬁcantly correlated with the therapy parameters. In
some cases however, the modeled insulin sensitivity seems to
underestimate the value set by the physician. At this point
it is hard to know whether the real value is overestimated
by the physician (for safety purposes), or underestimated by
the model, or both. The TPM also slightly overestimates the
insulin-to-carbohydrates ratio set by the physician. If the TPM
Table 6 – Comparative table of model properties.
MM LMM TPM
Simple
√  √ √
Acceptable data ﬁts
√  √ √
Identiﬁable × √ √
Linear × √ √
Acceptable predictions × √ √
Correlation with therapy parameters × × √
Number of parameters to identify 6 6 4ard deviations on the right.
would have been used for control, this would have resulted
in higher insulin injections. In the context of this study this
would not have been detrimental as insulin boluses were gen-
erally too small during the standard therapy experiments.
We can conclude that with the TPM, parameters are more
reliably and safely identiﬁed, compared to the LMM  and MM.
This is a clear hint that the TPM model structure is more
appropriate for BG predictions. Conversely, this nice feature
of the TPM model could make it a valuable tool for assisting
physicians in determining the therapy parameters.
4.2.3.  BG  predictions
The BG prediction analysis follows the same principle as
described in Section 4.1.3, but again with  ˛ as described in Sec-
tion 4.2.1. Also this time the cross-validation leads to up to 7
parameter sets per patient and gives a total of 58 parameter
sets.
Two examples of BG predictions with h = 90 are plotted in
Fig. 12, with on the left-hand side a relatively good prediction
and on the right-hand side a less successful one.
Initial BG concentration is noisy because it depends on
real measurements. This directly inﬂuences BG predictions
and can lead in some cases to wrong predictions. This does
not preclude the representativity of the comparison as the
same initialization method is applied to every tested model.
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f course, a more  elaborate initial state estimation (e.g. using
 Kalman ﬁlter) may lead to more  accurate predictions, but is
eyond the scope of this paper.
As can be seen in Fig. 13, the mean MAD  for the TPM and
MM  are almost equal, the latter only having a slightly lower
tandard deviation. The MM is less effective, especially with
mall prediction horizons, where predictions are worse than
ith the ZOH. The mean percentage of predictions in EGA
one A leads to a similar conclusion – this time the TPM being
arginally better and having smaller standard deviations than
he LMM.
On average, 97% of predictions for TPM and LMM are in
ones A and B for the EGA. This means that nearly no wrong
reatment decisions would be taken, even for long prediction
orizons. The MM goes down to 94%, whereas the ZOH goes
o 88%.
Predictions do not signiﬁcantly differ between the three
odels – a difference occurs mainly if, during identiﬁcation,
 model’s global minimum does not coincide with the actual
atient dynamics. This happens mostly with the MM, which
s due to the less favorable model dynamics. These outliers
hange the average and are the main reason for the differences
etween the different models in Fig. 13.
Overall the TPM always shows superior or comparable
rediction capabilities. This is particularly interesting consid-
ring that it only requires 4 parameters to identify and it
ompensates for its slightly inferior ﬁtting capabilities.
As a concluding remark, it should be noted that the dif-
erent days of the clinical study were very similar, which most
ikely makes predicting BG easier. With more  varied scenarios,
ome of the tested models could prove inappropriate. It would
herefore be interesting to test the model in a more  diverse
etting, similar to the previous analysis on UVa simulator
ata, however this is not possible with the currently available
ata.
.3.  Comparison  of  results  of  the  UVa  simulator  data
nd clinical  data
esults found with the UVa simulator data and clinical data are
onsistent. The TPM is the best choice in both cases because
f improved BG predictions and parameter correlation, while
aving less parameters. One main difference is the relative
erformance of the LMM  and the MM:  LMM  is better on clinical
ata, while the MM is better on UVa simulator data. This is
robably due to the fact that the MM dynamics are closer to the
Va simulator and its non-linearity, while the LMM dynamics
re closer to real human glucose dynamics.
.  Conclusion
he TPM measures up to the expectations of being a reliable
ut simple prediction model identiﬁable on BG measurements
nly. Stripping the model to a bare minimum allows reliable
arameter identiﬁcation, even in the presence of the charac-
eristic high noise levels in BG measurements. We  linked the
odel parameters directly to physician-set therapy parame-
ers and showed their strong correlation. This adds another
afety layer to the resulting model identiﬁcation and the o m e d i c i n e 1 1 8 ( 2 0 1 5 ) 107–123 121
model may easily be personalized. Additionally, the TPM may
be used to support physicians in determining patients’ therapy
parameters.
As expected, model ﬁts were slightly worse than with other
models – a result of the lower number of identiﬁed parameters.
However, model predictions were on par or slightly better than
the alternatives, even though the improvement is not statisti-
cally signiﬁcant. A higher number of parameters is therefore
not necessary.
Predictions are used to calculate insulin doses and as such
are critical for patient safety. If carefully identiﬁed, the TPM
leads to reliable insulin sensitivity estimation, which is rarely
the case with other models identiﬁed under the same condi-
tions. As such, the TPM may be used to assist physicians in
determining therapy parameters. Additionally, the TPM has
the property of only predicting an increase of BG concentration
in case of a meal. The possibility of predicting an erroneous
increase in BG is thus eliminated and hypoglycemia might be
avoided in certain cases, especially when used in closed-loop
controllers. Insulin infusions based on the TPM are therefore
safer than with conventional models.
The properties of the three prediction models are summa-
rized and compared in Table 6.
The TPM has been tailor-made for the use in state estima-
tion, predictive control, and recommendation methods, e.g.
Model Predictive Control (MPC), optimal control, or pump sus-
pension algorithms. As such it can be used under different
scenarios:
• For state estimation, i.e. for determining the BG concentra-
tions in the present:
- In the absence of CGM measurements, the TPM can be
used to estimate a patient’s current BG concentrations.
- If CGM measurements are available, it can be used to ﬁl-
ter the latter (using a Kalman ﬁlter, e.g.), to detect sensor
errors, or to detect system disturbances such as unan-
nounced meals.
-  Independently of CGM measurements, it can be used to
recommend additional SMBG measurements.
• For control and recommendation, i.e. for determining future
BG concentrations (this cannot be done by a CGM device),
the TPM can be used to:
- Compute optimal insulin infusions for optimal control
(open-loop control) or MPC (closed-loop control).
- Improve controllers using a Smith predictor.
- Automatically suspend or alter insulin pump infusions to
prevent hypoglycemia.
- Warn patients of impending hypo- or hyperglycemia and
recommend counteractive measures.
Future work will address the following points:
• The evolution of BG is a process with many  sources of uncer-
tainty that are not modeled in the TPM (and neither in any
other common models). It is therefore almost impossible
to have an accurate prediction of BG, even with the best
possible model and measurement devices. Future work will
focus on estimating the probabilistic distribution of BG pre-
dictions, because, considering the encountered noise levels,
signiﬁcantly more  accurate predictions or simpler models
 s i n
r122  c o m p u t e r m e t h o d s a n d p r o g r a m
seem unlikely. This would associate a conﬁdence interval to
any prediction, which is of high value. These results could
be applied in the context of robust control such as proposed
by, e.g., Kovács et al., Chee et al., or Palumbo et al. [37–39].
• The current TPM does not take physical activity into
account. Adding two additional states and parameters, sim-
ilarly to the insulin action sub-model, would probably lead
to an acceptable and more  detailed model. This will be
checked on clinical data in future work.
• The available clinical data used for validation was very sim-
ilar from one day to the other. The TPM should be tested on
more random test days to show its full potential.
• The TPM parameters are correlated to physician-set therapy
parameters. To improve identiﬁcation results, especially for
patients with few or noisy measurements, the physician set
parameters may be used as prior knowledge. Many meth-
ods applying Bayesian principles are available among which
population-based methods [13,24,40] that may perform well
and that will be investigated in the near future.
• The TPM should be tested on different meals and the meal
sub-model should be adapted if necessary.
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